2026-04-13T02:32:48Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1742922025-11-19T10:40:57Zcom_2072_1057col_2072_478815col_2072_478917

00925njm 22002777a 4500 dc Lizano Díez, Irene author Figueiredo Escribá, Carlos de author Piñero López, Maria Ángeles author Fernández Lastra, Cecilia author Mariño Hernández, Eduardo L. author Modamio Charles, Pilar author 2021-02-25T09:44:48Z 2021-02-25T09:44:48Z 2020-01-29 2021-02-25T09:44:48Z Background: Potential look-alike, sound-alike (LASA) errors in outpatient and inpatient prescriptions have been widely described worldwide. However, most strategies of reducing drug name confusion have been only focused on the processes of prescribing and dispensing, often following local rules. Main text: An illustrative recent example about this topic is given: the antidepressant Brintellix® (vortioxetine)(Takeda Pharmaceuticals USA, Inc.) and the antiplatelet medication Brilinta® (ticagrelor) (AstraZeneca LP). Revision of the initiatives that are currently applied to prevent potential LASA errors in different countries around the world and debate about the emerging strategies that could be implemented in short and mid-term. At present, a common policy worldwide on the authorization of unique names for innovative medicines does not exist. The implication of authorities in topdown strategies and the importance of developing an international health policy on the authorization of unique names for innovative medicines are highlighted in the following piece of opinion. Conclusions: Building and sustaining a culture of patient safety should be considered as a global top-down strategy which involved all the elements in the system (regulatory bodies, manufacturers and suppliers). The precedent established by the FDA in prevention strategies to identify and avoid LASA errors has been extremely important and should lead to international discussion. Coordinated international efforts are urgently needed in this area for the sake of patients' safety. Medicaments Seguretat dels pacients Prescripció de medicaments Equivalència terapèutica dels medicaments Drugs Patients safety Drug prescribing Therapeutic equivalency in drugs Prevention strategies to identify LASA errors: building and sustaining a culture of patient safety